GlaxoSmithKline scraps two key mid-stage trials for their ICOS drug in the latest setback for the field
Another ICOS cancer drug program is running into stormy weather, with more bad news for GlaxoSmithKline R&D chief Hal Barron.
GSK put out word on Wednesday evening that it has decided to scrap two mid-stage trials for feladilimab (GSK3359609) — an investigational inducible T cell co-stimulatory (ICOS) agonist — which wasn’t a huge surprise after Jounce got trounced with their mid-stage effort for vopratelimab last fall.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 124,200+ biopharma pros reading Endpoints daily — and it's free.